anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
atai Life Sciences · pitchdeck

ATAI | Investor Presentation Deck | 49 slides

49 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

ATAI | Investor Presentation Deck | 49 slides

atai Life Sciences · 2020-06
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 5 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 11 hits
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Traction 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Competition 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Financials 1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

49
every slide · same image gating as the playbook
01
Slide 1
Cover slide or mission statement slide.inspire_vision
Open slide detailLoop · Golden Circle
02
Includes date reference: June 13, 2022.other
Open slide detailLoop · Golden Circle
03
The slide uses a numbered list to present five key pillars of the company's value proposition.summarize
Open slide detailLoop · Golden Circle
04
The slide highlights key leadership figures and their past company affiliations, followed by a quantitative summary of their regulatory track record.summarize
Open slide detail
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.present_solution
Open slide detailBeat · Solution
06
The slide uses a Gantt-style visualization to show drug development progress.plan_implementation
Open slide detail
07
The slide uses a hub-and-spoke diagram to represent the company's decentralized model.present_solution
Open slide detail
08
The slide uses a timeline framework to contrast past performance with future expectations.plan_implementation
Open slide detail
09
transition
Open slide detail
10
The slide uses a split-layout: left side defines the condition and market size, right side outlines the clinical and regulatory pain points.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
11
The slide uses a line chart to demonstrate clinical efficacy over 12 weeks.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
12
Includes a dual-chart visualization comparing MADRS scores and CADSS scores from a third-party study.summarize
Open slide detail
13
The slide uses chemical structures and bar charts to contrast the two enantiomers.compare_peers
Open slide detailBeat · Competition
14
CADSS = Clinician Administered Dissociative States Scale. Data points are plotted over time (Baseline, 15m, 40m, 90m).analyze_data
Open slide detail
15
The slide uses a timeline diagram to illustrate the clinical trial phases.plan_implementation
Open slide detail
16
The table uses checkmarks to indicate positive attributes for specific compounds.compare_peers
Open slide detail
17
transition
Open slide detail
18
Uses a vertical timeline-style process diagram to list unmet needs.frame_problem
Open slide detail
19
The slide uses a vertical process flow to map development stages to key de-risking milestones.show_traction
Open slide detail
20
Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.summarize
Open slide detail
21
The slide highlights positive cognitive signals from a Phase 2 study, specifically emphasizing the efficacy of lower doses of RL-007.show_traction
Open slide detail
22
CIAS stands for Cognitive Impairment Associated with Schizophrenia. qEEG is quantitative electroencephalography.show_traction
Open slide detail
23
compare_peers
Open slide detail
24
transition
Open slide detail
25
The slide uses a combination of a list-based framework for the 'Massive Unaddressed Need' and a data-heavy section for 'Anxiety in numbers'.size_opportunity
Open slide detail
26
The slide uses a split-layout with a dark sidebar for key facts and a white main area for clinical data and trial design.summarize
Open slide detail
27
The slide uses a checkmark matrix to highlight the competitive advantage of the company's lead asset against standard-of-care classes like SSRIs, SNRIs, and Bencompare_peers
Open slide detail
28
transition
Open slide detail
29
The slide uses a combination of a map, metric callouts, and a vertical timeline-style list to quantify the market opportunity.size_opportunity
Open slide detail
30
Includes a line chart showing HCQN subscale scores over time and a process diagram for the ongoing trial.show_traction
Open slide detail
31
The table uses checkmarks to indicate positive attributes for various therapies, highlighting DMX-1002's unique profile.compare_peers
Open slide detail
32
transition
Open slide detail
33
The slide uses a Venn-like grouping of logos to illustrate the company's ecosystem.present_solution
Open slide detail
34
The slide uses a three-column layout to detail specific biotech subsidiaries/partnerships.present_solution
Open slide detail
35
The slide uses a split-screen layout to contrast the DTx platform (Psyber, Introspect) with the data analytics platform (Metabolomics, digital biomarkers, reseapresent_solution
Open slide detail
36
The slide uses a three-column layout to detail specific R&D approaches.present_solution
Open slide detail
37
transition
Open slide detailBeat · Financials
38
Includes a list of institutional investors at the bottom.show_traction
Open slide detail
39
appendix
Open slide detail
40
transition
Open slide detail
41
The table compares four different compounds (COMP360, VLS-01, RLS-01, PCN-101) across various clinical and commercial dimensions.compare_peers
Open slide detail
42
transition
Open slide detail
43
The slide combines electrophysiological data (LTP) with behavioral cognitive model results to support the drug's mechanism and efficacy.present_solution
Open slide detail
44
The slide highlights that RL-007 reverses memory deficits at the lowest dose and outperforms the standard of care (Aricept).show_traction
Open slide detail
45
transition
Open slide detail
46
The slide uses a split timeline to contrast early research with modern regulatory progress, punctuated by a Nixon quote.argue_timing
Open slide detail
47
The slide uses a yellow background with three distinct columns for testimonials, each featuring a headshot, demographic info, and the substance used.illustrate_case
Open slide detail
48
The slide highlights potential expansion beyond mental health into anti-inflammatory and other CNS-related therapeutic areas.size_opportunity
Open slide detail
49
inspire_vision
Open slide detail